Key Development
Ifinatamab deruxtecan produced notable responses in one of the most aggressive cancers. But compelling tumor shrinkage and a sufficiently strong regulatory package are not the same thing.
On September 25, 2026, Merck and Daiichi Sankyo voluntarily withdrew the U.S. BLA seeking accelerated approval of ifinatamab deruxtecan (I-DXd) for adults with extensive-stage small cell lung cancer that had progressed on or after platinum-based chemotherapy. The companies said discussions with FDA concluded that the available dataset, including the Phase 2 IDeate-Lung01 study, did not meet requirements to support accelerated approval for the proposed indication.
I-DXd is a B7-H3-directed antibody-drug conjugate built on Daiichi Sankyo’s DXd platform. In 137 previously treated patients receiving 12 mg/kg in IDeate-Lung01, confirmed ORR was 48.2%, median duration of response was 5.3 months, median PFS 4.9 months and median OS 10.3 months. Among a smaller second-line subgroup, ORR reached 56.3% with median DoR of 7.2 months. But the study remained single-arm, without a randomized comparator.
Development continues. Enrollment is nearly complete in the randomized Phase 3 IDeate-Lung02 trial comparing I-DXd against physician’s choice of amrubicin, lurbinectedin or topotecan, and the companies intend to evaluate a future regulatory filing based on those results.
Why It Matters
- A strong response rate no longer guarantees an accelerated pathway. FDA’s oncology guidance states that randomized controlled trials are preferred because they allow more robust assessment of efficacy and safety than single-arm studies.
- The SCLC competitive benchmark has moved. Tarlatamab received traditional approval in 2025 after a randomized trial showed median OS of 13.6 months versus 8.3 months with standard chemotherapy.
- ADC efficacy must be balanced against payload toxicity. In IDeate-Lung01, 36.5% of patients experienced grade ≥3 treatment-related adverse events. Confirmed treatment-related ILD/pneumonitis occurred in 12.4%, including two grade 5 events.
- This is the second U.S. withdrawal among the three ADCs in the Merck–Daiichi alliance. Patritumab deruxtecan’s NSCLC application was withdrawn in 2025 after the confirmatory Phase 3 study failed to show a statistically significant OS benefit.
Healthcare Insight Analysis
Healthcare Insight believes this should not be framed simply as “another ADC failure.”
I-DXd’s clinical program remains active. B7-H3 is still a biologically attractive target with no approved B7-H3-directed cancer medicine, and I-DXd is also being developed beyond SCLC.
What has changed is the evidence environment.
Lurbinectedin received accelerated approval in relapsed SCLC in 2020 based on a single-arm study with an ORR of 35% and a median DoR of 5.3 months. I-DXd has now reported a higher numerical ORR of 48.2% with the same median response duration. Those figures cannot be compared as proof of superiority across different trials — but they reveal something important about regulation: the approval threshold is contextual, not static.
The SCLC market in 2026 is materially different.
Tarlatamab has already produced randomized evidence of improved overall survival against standard chemotherapy. Once a therapy demonstrates that level of benefit, a new entrant is entering a market where tumor shrinkage alone carries less persuasive power.
The regulatory question therefore evolves from:
“Does the tumor respond?”
to:
“Does the treatment materially improve the patient’s clinical outcome relative to what is now available?”
That shift has broader implications for the ADC sector.
The first wave of ADC enthusiasm rewarded three attributes: a recognizable tumor target, a potent payload and impressive early response rates.
The next phase will demand three harder proofs:
target biology + therapeutic index + randomized clinical benefit.
I-DXd illustrates why the second element matters. ADCs are often described as targeted “guided missiles,” but the cytotoxic payload can still generate systemic toxicity. Interstitial lung disease/pneumonitis and hematologic toxicity remain meaningful parts of I-DXd’s benefit–risk equation.
The Phase 3 study is therefore more than a confirmatory exercise. It is the trial that can determine whether I-DXd’s response activity translates into a therapy capable of beating real-world alternatives.
Market Implications
Merck: the setback increases scrutiny on a major ADC investment intended to contribute to long-term oncology growth beyond Keytruda. The 2023 collaboration carried potential consideration of up to $22 billion across three DXd ADCs.
Daiichi Sankyo: the DXd platform remains strategically valuable, but two regulatory withdrawals demonstrate that platform strength does not make every target clinically or commercially successful.
ADC developers: single-arm Phase 2 ORR may increasingly function as a capital-allocation signal rather than an assumed shortcut to market.
Oncology investors: greater weight should go to randomized pivotal evidence, durability and therapeutic index rather than extrapolating blockbuster potential directly from early response data.
ANALYTICAL MATRIX
| Dimension | Current Signal | Opportunity | Key Risk |
|---|---|---|---|
| Efficacy | ORR 48.2%; DoR 5.3 months | Meaningful SCLC activity | No randomized superiority yet |
| Safety | Targeted ADC architecture | Potential therapeutic window | ILD/pneumonitis and cytopenias |
| Regulatory | Accelerated BLA withdrawn | New filing possible after Phase 3 | Higher evidence threshold |
| Portfolio | Major Merck–Daiichi asset | B7-H3 across multiple tumors | Two alliance withdrawals |
| Competition | Significant unmet need remains | Space for differentiated therapy | Tarlatamab has randomized OS benefit |
The two decisive next signals are overall survival and overall benefit–risk from IDeate-Lung02, and whether I-DXd can demonstrate advantage against an active comparator rather than historical expectations.
If Phase 3 succeeds, the 2026 withdrawal may ultimately be a regulatory delay. If it does not, the broader lesson will be harder to ignore: the ADC boom is moving from an era of impressive response rates to an era where platforms must prove they can change survival and treatment standards.